The present invention is directed to azetidine compounds that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurological and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved.

 
Web www.patentalert.com

< L-Threonine derivatives of high therapeutic index

> Ion channel modulating activity method

> Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
~ 00537